Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
Biogen(BIIB) stock is priced at $181.31, giving the company a market capitalization of 26.6B. It carries a P/E multiple of 16.60.
During the trading session on 2025-12-05, Biogen(BIIB) shares reached a daily high of $183.15 and a low of $181.10. At a current price of $181.31, the stock is +0.1% higher than the low and still -1.0% under the high.
Trading activity shows a volume of 1.21M, compared to an average daily volume of 1.89M.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
BIIB News
(RTTNews) - Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studi...
Biogen (BIIB) and Stoke Therapeutics (STOK) announced data presentations that further support the potential of zorevunersen, an investigational antisense oligon...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the January 2026 expiration. At Stock Options Channel , our YieldBoost formul...
Analyst ratings
50%
of 36 ratingsMore BIIB News
In late November and early December 2025, Eisai and Biogen reported new LEQEMBI (lecanemab) data at the CTAD conference, highlighting long-term “time savings” i...
Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta...
Curious if Biogen is a bargain or overpriced in today’s market? You’re not alone. A fresh look at its valuation might challenge what you think you know. After...
Biogen (BIIB) just announced a new research partnership with Dayra Therapeutics focused on developing oral macrocyclic peptides for immunological conditions. Th...